A functional polymorphism rs4938723 in the promoter of miR-34b/c is associated with an increased risk of lung cancer
A functional polymorphism rs4938723 in the promoter of miR-34b/c
DOI:
https://doi.org/10.47743/jemb-2024-121Keywords:
Lung cancer, polymorphisim, SNP, miR-34a, miR-34b/c, miR-125aAbstract
Background: The expression level of some microRNAs (miRNAs) in lung cancer has been associated with an increased risk of cancer. miRNAs play a substantial role in the pathogenesis of human cancers. Because of that, miRNA polymorphisms can be important for carcinogenesis. MiR-34 is a family of miRNAs known to have reduced levels of expression in lung cancer and other human cancers (pancreas, colon). It functions like tumor suppressor and targets oncogenes like MET, RET, and RAB43. Also miR-125 family is related with many cancer types and targets P53, BCL2, VEGF, and EGFR.
References
Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26: 745–752. DOI: https://doi.org/10.1016/j.molcel.2007.05.010
Chen CL, Hsu LI, Chiou HY, Hsueh YM, Chen SY, Wu MM, et al. Ingested arsenic, cigarette smoking, and lung cancer risk: A follow-up study in arseniasis-endemic areas in Taiwan. JAMA 2004; 292: 2984. DOI: https://doi.org/10.1001/jama.292.24.2984
Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer 2016; 6: 259–269. DOI: https://doi.org/10.1038/nrc1840
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer 2015; 136(5). DOI: https://doi.org/10.1002/ijc.29210
Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105. DOI: https://doi.org/10.1101/gr.082701.108
Fu Y, & Cao F. MicroRNA-125a-5p regulates cancer cell proliferation and migration through NAIF1 in prostate carcinoma. OncoTargets and therapy 2015; 8: 3827. DOI: https://doi.org/10.2147/OTT.S92314
Gallardo E, Navarro A, Viñolas N, Marrades RM, Diaz T, Gel B, et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 2009; 30(11): 1903-1909. DOI: https://doi.org/10.1093/carcin/bgp219
Gong J, Tong Y, Zhang HM, Wang K, Hu T, Shan G, et al. Genome-wide identification of SNPs in microRNA genes and the SNP effects on microRNA target binding and biogenesis. Human Mutation 2012; 33(1): 254-263. DOI: https://doi.org/10.1002/humu.21641
Hashiguchi Y, Nishida N, Mimori K, Sudo T, Tanaka F, Shibata K, et al. Down-regulation of miR-125a-3p in human gastric cancer and its clinicopathological significance. International journal of oncology 2012; 40(5): 1477-1482.
Hermeking, H. The miR-34 family in cancer and apoptosis. Cell death and differentiation 2010; 17(2): 193. DOI: https://doi.org/10.1038/cdd.2009.56
Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65: 7065–7070. DOI: https://doi.org/10.1158/0008-5472.CAN-05-1783
Iwai N, Naraba H. Polymorphisms in human pre-miRNAs. Biochemical and biophysical research communications 2015; 331(4): 1439-1444. DOI: https://doi.org/10.1016/j.bbrc.2005.04.051
Jiang L, Huang Q, Zhang S, Zhang Q, Chang J, Qiue X, t al. Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells. BMC cancer 2010; 10(1): 318. DOI: https://doi.org/10.1186/1471-2407-10-318
Jiang, H., Ge, F., Hu, B., Wu L, Yang H, Wang H. rs35301225 polymorphism in miR-34a promotes development of human colon cancer by deregulation of 3′ UTR in E2F1 in Chinese population. Cancer cell international 2017; 17(1): 39. DOI: https://doi.org/10.1186/s12935-017-0402-1
Jiao L, Zhang J, Dong Y, Duan B, Yu H, Sheng H. et al, Association between miR-125a rs12976445 and survival in breast cancer patients. American journal of translational research 2014; 6(6): 869.
Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J. Exploration of tumor suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res. 2008; 68: 2094–2105. DOI: https://doi.org/10.1158/0008-5472.CAN-07-5194
Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11(9): 597–610. DOI: https://doi.org/10.1038/nrg2843
Lehmann TP, Korski K, Ibbs M, Zawierucha P, Grodecka-Gazdecka S, Jagodzinski PP. rs12976445 variant in the pri‑miR‑125a correlates with a lower level of hsa‑miR‑125a and ERBB2 overexpression in breast cancer patients. Oncology letters 2013; 5(2): 569-573. DOI: https://doi.org/10.3892/ol.2012.1040
Li L, Wu J, Sima X, Bai P, Deng W, Deng X, et al. Interactions of miR-34b/c and TP-53 polymorphisms on the risk of nasopharyngeal carcinoma. Tumor Biology 2013; 34(3): 1919-1923. DOI: https://doi.org/10.1007/s13277-013-0736-9
Li W, Duan R, Kooy F, Sherman SL, Zhou W, Jin P. Germline mutation of microRNA-125a is associated with breast cancer. J Med Genet 2009; 46(5): 358–60. DOI: https://doi.org/10.1136/jmg.2008.063123
Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Körner H, et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008; 7: 2591–2600. DOI: https://doi.org/10.4161/cc.7.16.6533
Na II, Byun, BH, Kim KM, Cheon GJ, Choe DH, et al. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis. Lung Cancer 2010; 67(1): 76-80. DOI: https://doi.org/10.1016/j.lungcan.2009.03.010
Nishida N, Mimori K, Fabbri M, Yokobori T, Sudo T, Tanaka F, et al. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res. 2011; 17: 2725–2733. DOI: https://doi.org/10.1158/1078-0432.CCR-10-2132
Pan XM, Sun RF, Li ZH, Guo XM, Qin HJ, Gao LB, et al. Pri-miR-34b/c rs4938723 polymorphism is associated with a decreased risk of gastric cancer. Genetic testing and molecular biomarkers 2015; 19(4): 198-202. DOI: https://doi.org/10.1089/gtmb.2014.0287
Quan H, Yuan T, Hao J. A microRNA‑125a variant, which affects its mature processing, increases the risk of radiation‑induced pneumonitis in patients with non‑small‑cell lung cancer. Molecular Medicine Reports 2018; 18: 4079-4086. DOI: https://doi.org/10.3892/mmr.2018.9406
Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome Res 2004; 14: 1902–1910. DOI: https://doi.org/10.1101/gr.2722704
Shastry BS. SNPs: impact on gene function and phenotype. Methods Mol. Biol. 2009; 578: 3-22. DOI: https://doi.org/10.1007/978-1-60327-411-1_1
Shields, Peter G. Molecular epidemiology of smoking and lung cancer. Oncogene, 2002, 21(45): 6870-6876. DOI: https://doi.org/10.1038/sj.onc.1205832
Son MS, Jang MJ, Jeon YJ, Kim WH, Kwon CI, Ko KH, et al. Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma. Gene 2013; 524(2): 156-160. DOI: https://doi.org/10.1016/j.gene.2013.04.042
Spitz MR, Hong WK, Amos CI, Wu X, Schabath MB, Dong Q, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst. 2007; 99: 715-26. DOI: https://doi.org/10.1093/jnci/djk153
Sun YM, Lin KY, Chen YQ. Diverse functions of miR-125 family in different cell contexts. Journal of hematology & oncology 2013; 6(1): 6. DOI: https://doi.org/10.1186/1756-8722-6-6
Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomuraet Y, et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 2008; 68: 4123–4132. DOI: https://doi.org/10.1158/0008-5472.CAN-08-0325
Wang RJ, Zheng YH, Wang P, Zhang JZ, et al. Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer. International journal of clinical and experimental pathology 2015; 8(1): 765.
Wang S, Huang J, Lyu H, Lee CK, Tan J, Wang J, Liu B. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells. Cell death & disease 2013; 4(3): e556. DOI: https://doi.org/10.1038/cddis.2013.79
Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007; 26(34): 5017. DOI: https://doi.org/10.1038/sj.onc.1210293
Wynendaele J, Bohnke A, Leucci E, Nielsen SJ, Lambertz I, Hammer S, et al. An illegitimate microRNA target site within the 3′ UTR of MDM4 affects ovarian cancer progression and chemosensitivity. Cancer Res. 2010; 70(23): 9641–9. DOI: https://doi.org/10.1158/0008-5472.CAN-10-0527
Xu Y, Liu L, Liu J, Zhang Y, Zhu j, Chen J, et al. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer 2011; 128: 412–417. DOI: https://doi.org/10.1002/ijc.25342
Yan D, Zhou X, Chen X, Hu DN, Dong XD, Wang J, et al. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. Invest. Ophthalmol. Vis. Sci. 2008; 50: 1559-1565). DOI: https://doi.org/10.1167/iovs.08-2681
Yin J, Wang X, Zheng L, Shi Y, Wang L, Shao A, et al. Hsa-miR-34b/c rs4938723 T> C and hsa-miR-423 rs6505162 C> A polymorphisms are associated with the risk of esophageal cancer in a Chinese population. PloS one 2013; 8(11): e80570. DOI: https://doi.org/10.1371/journal.pone.0080570
Yuan F, Sun R, Chen P, Liang Y, Ni S, Quan Y, et al. Combined analysis of pri-miR-34b/c rs4938723 and TP53 Arg72Pro with cervical cancer risk. Tumor Biology 2016; 37(5): 6267-6273. DOI: https://doi.org/10.1007/s13277-015-4467-y
Zang Z, Guan W, Chen D, Han Y, Shi Z, Zhou J. Association Between microRNA-125a rs12976445 C> T Polymorphism and 18F-Fluorodeoxyglucose (18FDG) Uptake: Clinical and Metabolic Response in Patients with Non-Small Cell Lung Cancer. Medical science monitor: international medical journal of experimental and clinical research 2016; 22: 4186. DOI: https://doi.org/10.12659/MSM.897255
Downloads
Published
How to Cite
License
Copyright (c) 2024 Ercan ARICAN, Aycan ÇELİK, Sevim Karakas Celik, Erkan Arpacı, Hüseyin Ergin
This work is licensed under a Creative Commons Attribution 4.0 International License.
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. The journal allows readers to read, download, copy, distribute, print, search, link to the full texts or use the articles for any other lawful purpose.
The authors are the sole copyright owners of the published articles. The articles are distributed under the CC BY 4.0 license to the readers.
The readers are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — you may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Reviewer Recognition Service. Forward your thank you e-mail to 
